Dr Reddy’s to launch 15-16 products in the US market

Dr Reddy’s to launch 15-16 products in the US marketIndian pharmaceutical major, Dr Reddy's Laboratories is planning to launch as many as 15 to 16 new products in the Us market in the year.

The expanded product line is expected to contribute about one-third to its revenues. The company had launched 12 products in the US market in the previous fiscal year and has generated about Rs3,189 crore in revenues.

Satish Reddy, the company's chief operating officer said, "There are going to be some interesting products. This year is a busy year and there are quite a few launches."

The company owns 80 abbreviated new drug applications that are yet to receive approval by the US Food and Drug Administration (FDA) and about seven

has about 80 abbreviated new drug applications (Andas) pending for approval by the US Food and Drug Administration (FDA) and about seven of them have first-to-file (FTF) status and about seven of the drugs already have first-to-file (FTF) status.

Dr Reddy's Laboratories has reported a rise of 2.46 per cent in consolidated net profit to Rs 342.70 crore for the fourth quarter for the financial year till March 2012.

The company had recorded a net profit of Rs 334.47 crore during the same period of previous fiscal year, according to a fling by the company with the Bombay Stock Exchange (BSE). The net income of the company increased to Rs 2,658.45 crore during quarter compared to Rs 2,017.27 crore in the same quarter of the previous fiscal year. The company's net sales rose 32 per cent to Rs 2,658.5 crore during the fourth quarter.

As for the whole financial year, the company recorded a net profit of Rs 1,426.21 crore compared to Rs 1,104 crore in 2010-11 fiscal. Its net income from sales and service for the whole year was at Rs 9,673.74 crore, compared to Rs 7,469.28 crore in the previous fiscal.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate